Skip to content

A randomized controlled clinical trial of mindfulness-based cognitive therapy in prognosis of primary angle-closure glaucoma

A randomized controlled clinical trial of mindfulness-based cognitive therapy in prognosis of primary angle-closure glaucoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500098534
Enrollment
Unknown
Registered
2025-03-10
Start date
2025-03-17
Completion date
Unknown
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary angle-closure glaucoma

Interventions

Mindfulness-based cognitive therapy intervention group:To combine mindfulness-based cognitive therapy on the basis of patients' original anti-glaucoma therapy
Observation group:Only the patients' original anti-glaucoma therapy will be kept

Sponsors

Beijing Chaoyang Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Participants' age should be ranged from 40 to 80 years; 2) Participants should be diagnosed with primary angle-closure glaucoma: with or without the symptom of repeated mild to moderate increases in intraocular pressure, with peripheral anterior chamber shallow, with moderately narrow anterior chamber angle and with different extent of peripheral anterior synechiae; 3) Participants should be willing to cooperate and follow up.

Exclusion criteria

Exclusion criteria: 1) Secondary glaucoma; 2) Patients who may undergo cataract or filtration surgery during the collaboration; 3) Combined with other eye diseases that may affect vision and visual field: uveitis, retinal arterial or vein obstruction, age-related macular disease, optic neuritis, etc; 4) Patients who have practiced yoga and mindfulness before.

Design outcomes

Primary

MeasureTime frame
N95 amplitude in electroretinogram;

Secondary

MeasureTime frame
GAD-7 anxiety scale score;PHQ-9 depression scale score;Best corrected visual acuity;Intraocular pressure;Optometr;Visual field;Retinal nerve fiber layer thickness;Retinal vascular density;Retinal vascular perfusion;The level of cortisol in blood;The level of IL-6 in blood;The level of TNF-a in blood;The level of MDA in blood;The level of NOS3 in blood;

Countries

China

Contacts

Public ContactMaoren Wang

Beijing Chaoyang Hospital Affiliated to Capital Medical University

wmaoren@163.com+86 186 8722 9830

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026